Mesude Bicak

Icahn School of Medicine at Mount Sinai — United States

Immunology and Microbiology · Life Sciences

14h-index1.2kcitations72works1.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immunotherapy and Immune Responses(14), vaccines and immunoinformatics approaches(14), Monoclonal and Polyclonal Antibodies Research(13), Prostate Cancer Treatment and Research(10), Radiopharmaceutical Chemistry and Applications(7)

Publications71 total

A tumor-promoting inflammatory SPP1+ macrophage—IL-6—CRP axis drives immune dysfunction in bladder cancer
Cancer Discovery·2026
Supplementary Figures 1 and 2 from Quantitative <i>In Vivo</i> Imaging of the Androgen Receptor Axis Reveals Degree of Prostate Cancer Radiotherapy Response
2025Open Access
Identifying targets of precancerous neoantigen-specific T cell surveillance in patients with Lynch syndrome and immune suppression programs supporting colorectal cancer progression 3671
The Journal of Immunology·2025Open Access
miR155 triplicated in Down syndrome regulates hippocampal GABAergic neurogenesis in Alzheimer’s disease
2025Open Access
Supplementary Table5 from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
2025Open Access
Supp Fig4+ Legend from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
2025Open Access
Supplementary Table3 from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
2025Open Access
Supp Fig3 + Legend from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
2025Open Access
Supp Fig2 + Legend from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
2025Open Access
Data from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
2025Open Access
Supp Fig6+ Legend from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
2025Open Access
Supplementary Table4 from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
2025Open Access
Supp Fig7+ Legend from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
2025· 1 citedOpen Access
Supplementary Table1. from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
2025Open Access
Supplementary Table2 from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
2025Open Access
Supp Fig5+ Legend from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
2025Open Access
Supp Fig1+ Legend from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
2025Open Access
PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
Cancer Discovery·2025· 12 cited
1350 Dissecting immune surveillance and escape in Lynch syndrome patients
Regular and Young Investigator Award Abstracts·2024Open Access
Mapping shared neoantigens and T-cell dysregulation in MSI-H endometrial cancer patients
Gynecologic Oncology·2024
page 1 of 4Next →

Frequent Co-authors

Cansu Cimen Bozkus(13), Nina Bhardwaj(13), Benjamin S. Glicksberg(10), Mansi Saxena(10), Thomas U. Marron(10), Julia Kodysh(10), John P. Finnigan(10), Sayali Onkar(10), Anna Kaminska(10), Kevin Tuballes(10), Ruiwei Guo(10), Marcia Meseck(10), Timothy J. O’Donnell(10), Robert Sebra(10), Samir Parekh(10), Matthew D. Galsky(10), Ana Blasquez(10), Gustavo Giménez(10), Daniela Delbeau-Zagelbaum(10), Denise Rodriguez(10)